Crosstree Capital Partners advised Seres Laboratories Incorporated in it's sale to Nanosyn. Crosstree was able to help close the deal in less than a month.
Please direct inquiries to:
Shane C. Senior, CFA
Crosstree Capital Partners, Inc.
Hit hard by the market downturn in 2009, Seres Laboratories Incorporated, an API manufacturer specializing in cGMP manufacturing, needed to sell or risk becoming another victim of the bad economy. Seres approached Crosstree advise on what strategic options it had, and decided on a sale. Not having much time, Crosstree reached out to Nanosyn, knowing that they were looking for a site to expand their Joint-Venture with PCAS.
Nanosyn confirmed interest and Crosstree helped the companies with due diligence with no real process in place. In the end, Crosstree was able to help broker the deal in less than a months time causing no breaks in operation to occur at Seres' facility. A few months after the acquisition, Nanosyn and PCAS were able to have the transition completed at the plant and rebranded under the JV PCAS-NANOSYN, LLC.
Seres Laboratories Incorporated is a research-based company specializing in CGMP through Phase III and non-CGMP syntheses (milligrams to kilograms) of high purity complex organic molecules for the biotechnology and pharmaceutical industries. Seres offers Contract Process Development services to verify and scale up client-provided chemical syntheses or to design synthetic processes from the literature.
Nanosyn is a privately held chemistry-based enterprise founded in 1998 by a group of industry experts specializing in the design, synthesis, and analysis of small molecule organic compounds for the pharmaceutical industry. The company' s client base consists of pharmaceutical, biotech, and academic institutions. Nanosyn has a well established track record, encompassing well over a hundred business relationships throughout the United States and the rest of the world. Nanosyn is located in the center of Biotech Bay TM’s hotbed in Menlo Park, California.
Menlo Park, CA - PCAS, a worldwide leader in commercial scale pharmaceutical synthesis and fine and specialty chemical manufacturing, and Nanosyn, a leading US based pharmaceutical contract research provider of preclinical chemistry and biology services, announce the signing of a joint-venture agreement to operate PCAS-NANOSYN, LLC, a Good Manufacturing Practice (cGMP) kilolab in Santa Rosa, Northern California.
The newly created company, PCAS-NANOSYN, LLC, will enable PCAS and Nanosyn to satisfy a broader range of customer needs in the pharmaceutical and biotech marketplaces by offering fully integrated custom chemical services from discovery to commercialization.
"The formation of this JV with such a reputable partner as we have found in Nanosyn allows us to place critical preclinical and clinical trial API synthetic capabilities nearer to our clients in the US," said Christian Moretti, Chairman of PCAS, "It is an ideal next step in our strategy to continue growing our customer base in North America and builds on the success of our PCAS America marketing office in New Jersey."
The joint venture operation will provide services out of an FDA inspected facility in Santa Rosa, California, housing six (GMP) suites, two of which are certified as Class 10,000 clean rooms. PCAS-Nanosyn, LLC customers will further benefit from the significant chemical and analytical resources within the parent companies, and the ability to seamlessly transfer projects for larger scale to PCAS' network of four FDA inspected pilot and commercial scale plants in Europe.
"We are excited to offer this suite of cGMP solutions as a result of this partnership. For our clients, this is a natural extension of Nanosyn's highly successful discovery services into process development, scale-up, and supply of preclinical and cGMP clinical trial quantities of APIs." said Nikolai Sepetov, President and CEO of Nanosyn, Inc., "Ensuring quality, start to finish, is fundamental to the success we share with our clients."
Currently, the PCAS-NANOSYN, LLC. facility is fully operational and is founded on the assets of Seres Laboratories. Nanosyn acquired the physical assets of Seres in March of 2009 and retained its experienced staff in order to take advantage of its 30 year history as an FDA registered cGMP site. As part of PCAS-NANOSYN, LLC strategy to be the premier provider of high quality and cost efficient services for the pharmaceutical and biotechnology industries, the joint venture plans to expand the site by upgrading its existing R&D and analytical capabilities, while adding new, advanced capacities. Olga Issakova, Ph.D., Executive Vice President of Nanosyn, Inc., will serve as CEO of the newly formed company.
Crosstree Capital Partners was the exclusive advisor for Seres Laboratories Incorporated in it's sale to Nanosyn.
Crosstree Capital Partners is a specialty advisory firm with a dedicated focus on select subsectors of the life sciences and healthcare industries, including drug and device outsourcing, diagnostic products and services, life sciences tools, medical technology, and healthcare information technology. Within these subsectors, Crosstree assists clients with corporate finance activities, including mergers and acquisitions advisory and growth capital financings. Crosstree's deep sector coverage offers clients unique industry insights, well-established strategic relationships across the globe and superior access to the capital markets. While Crosstree draws distinct industry lines of coverage, the firm has no geographic boundaries. Crosstree has advised clients throughout North America, Europe, India, China, Latin America and Australia. Crosstree Capital Partners, Inc. is an affiliate of Crosstree Capital Securities, LLC, which is a member of FINRA and SIPC. Crosstree’s website is http://www.crosstreecapital.com.
Crosstree Capital Partners is a micro-industry focused investment bank, providing strategic advisory services, including mergers and acquisitions, recapitalizations, and growth capital placements, to leading clients within its focused industries.
Crosstree is the leading source of related valuation and transactional data for its focus industries. Publications are available exclusively to website subscribers on dedicated industry portals. To access Crosstree’s proprietary industry portals and related publications and data, please login or click here to join.
Copyright © 2012 • Crosstree Capital Partners • All rights reserved•